Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Fibroblast Growth Factor Receptor 3 (FGFR3) Expression in Malignant Lymphomas

Fibroblast Growth Factor Receptor 3 (FGFR3) Expression in Malignant Lymphomas Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE Fibroblast Growth Factor Receptor 3 (FGFR3) Expression in Malignant Lymphomas Andrew Larson, DO and James R. Cook, MD, PhD acquired activating mutations of FGFR3 have been Abstract: Fibroblast growth factor receptor 3 (FGFR3) protein described in malignancies such as cervical or bladder 3,5 is aberrantly expressed in approximately 15% of cases of plasma carcinomas. Aberrant expression of FGFR3 also cell myeloma as a result of t(4;14)(p16.3;q32), and FGFR3 occurs in approximately 15% to 20% of plasma cell 6–9 expression in myeloma is associated with an adverse prognosis. myeloma, generally as a result of t(4;14)(p16.3;q32). Novel, recently developed therapeutic agents that target the Because cases of myeloma with FGFR3 overexpression 10,11 FGFR3 pathway are currently in clinical trials for myeloma. are associated with an unfavorable prognosis, novel Although extensively studied in plasma cell neoplasms, there is therapeutic agents have been developed which specifically little information in the literature regarding FGFR3 expression target FGFR3 signaling or expression and show in vitro 12–15 in malignant lymphomas, and it is unclear whether lymphoma activity against FGFR3-positive myeloma cells. patients may also benefit from anti-FGFR3 therapy. We, Although many studies have examined FGFR3 10,11,16 therefore, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Fibroblast Growth Factor Receptor 3 (FGFR3) Expression in Malignant Lymphomas

Loading next page...
 
/lp/wolters-kluwer-health/fibroblast-growth-factor-receptor-3-fgfr3-expression-in-malignant-tjmR3tBlrs

References (31)

Publisher
Wolters Kluwer Health
ISSN
1541-2016
DOI
10.1097/PAI.0b013e31815ace54
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE Fibroblast Growth Factor Receptor 3 (FGFR3) Expression in Malignant Lymphomas Andrew Larson, DO and James R. Cook, MD, PhD acquired activating mutations of FGFR3 have been Abstract: Fibroblast growth factor receptor 3 (FGFR3) protein described in malignancies such as cervical or bladder 3,5 is aberrantly expressed in approximately 15% of cases of plasma carcinomas. Aberrant expression of FGFR3 also cell myeloma as a result of t(4;14)(p16.3;q32), and FGFR3 occurs in approximately 15% to 20% of plasma cell 6–9 expression in myeloma is associated with an adverse prognosis. myeloma, generally as a result of t(4;14)(p16.3;q32). Novel, recently developed therapeutic agents that target the Because cases of myeloma with FGFR3 overexpression 10,11 FGFR3 pathway are currently in clinical trials for myeloma. are associated with an unfavorable prognosis, novel Although extensively studied in plasma cell neoplasms, there is therapeutic agents have been developed which specifically little information in the literature regarding FGFR3 expression target FGFR3 signaling or expression and show in vitro 12–15 in malignant lymphomas, and it is unclear whether lymphoma activity against FGFR3-positive myeloma cells. patients may also benefit from anti-FGFR3 therapy. We, Although many studies have examined FGFR3 10,11,16 therefore,

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jul 1, 2008

There are no references for this article.